Mesa Laboratories (NASDAQ:MLAB) Given New $110.00 Price Target at Wells Fargo & Company

Key Points

• Wells Fargo raised Mesa Laboratories’ price target from $94 to $110 while maintaining an “equal weight” rating, implying about 1.82% downside from the prior close.
• Analyst sentiment remains neutral: Weiss Ratings upgraded the stock from “sell” to “hold,” while the broader consensus is “Hold” with an average target of $110.
• Mesa reported quarterly earnings of $2.68 per share on $60.14 million in revenue. Shares recently traded at $112.04, near their 12-month high of $115.52, with institutional investors owning 90.6% of the stock.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) had its target price boosted by analysts at Wells Fargo & Company from $94.00 to $110.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has an "equal weight" rating on the medical instruments supplier's stock. Wells Fargo & Company's price objective indicates a potential downside of 1.82% from the stock's previous close.

Separately, Weiss Ratings upgraded shares of Mesa Laboratories from a "sell (d)" rating to a "hold (c-)" rating in a research report on Tuesday. Three analysts have rated the stock with a Hold rating, According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $110.00.

Mesa Laboratories Stock Performance

Shares of MLAB stock traded down $1.16 on Friday, reaching $112.04. The stock had a trading volume of 48,149 shares, compared to its average volume of 147,655. The firm's 50-day moving average is $100.59 and its two-hundred day moving average is $95.90. The firm has a market capitalization of $626.97 million, a price-to-earnings ratio of 133.36 and a beta of 0.92. The company has a quick ratio of 1.29, a current ratio of 1.72 and a debt-to-equity ratio of 0.78. Mesa Laboratories has a 12 month low of $58.83 and a 12 month high of $115.52.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The medical instruments supplier reported $2.68 earnings per share for the quarter. Mesa Laboratories had a return on equity of 22.87% and a net margin of 1.92%.The business had revenue of $60.14 million for the quarter.

Insider Buying and Selling

In other news, CFO John Sakys sold 2,827 shares of the firm's stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $89.50, for a total value of $253,016.50. Following the completion of the sale, the chief financial officer directly owned 19,785 shares in the company, valued at $1,770,757.50. This trade represents a 12.50% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Lyndsey Elizabeth Crennen sold 442 shares of the business's stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $89.50, for a total value of $39,559.00. Following the completion of the sale, the chief accounting officer directly owned 2,020 shares of the company's stock, valued at $180,790. The trade was a 17.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 8,277 shares of company stock valued at $770,122 over the last ninety days. 2.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Mesa Laboratories

Large investors have recently modified their holdings of the company. Ranger Investment Management L.P. acquired a new position in Mesa Laboratories during the second quarter worth $17,321,000. Diamond Hill Capital Management LLC Investment Advisor purchased a new stake in shares of Mesa Laboratories during the 2nd quarter valued at $15,507,000. Boston Partners lifted its stake in Mesa Laboratories by 2,009.5% in the 3rd quarter. Boston Partners now owns 114,357 shares of the medical instruments supplier's stock worth $7,664,000 after purchasing an additional 108,936 shares in the last quarter. Millennium Management LLC increased its stake in Mesa Laboratories by 131.9% in the 3rd quarter. Millennium Management LLC now owns 133,817 shares of the medical instruments supplier's stock worth $8,967,000 after acquiring an additional 76,107 shares during the last quarter. Finally, Wasatch Advisors LP raised its stake in Mesa Laboratories by 125.8% in the second quarter. Wasatch Advisors LP now owns 115,668 shares of the medical instruments supplier's stock valued at $11,515,000 after purchasing an additional 64,435 shares in the last quarter. 90.60% of the stock is currently owned by institutional investors.

About Mesa Laboratories

Mesa Laboratories, Inc NASDAQ: MLAB is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company's product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source